On high-speed rotary tablet presses processing veterinary-grade flufenoxuron for companion animal ectoparasite programmes where regional registration permits oral administration, direct compression is preferred over aqueous wet granulation because the benzoylurea active is hydrophobic and can form hard agglomerates when exposed to granulator moisture above 3% w/w. Spiral jet milling of the API to D90 ≤ 20 µm is required for blend homogeneity at tablet strengths below 25 mg; the milled material is incorporated into a pre-blend of spray-dried lactose monohydrate and pregelatinized maize starch in a diffusion mixer operated at 8–12 rpm for 15–20 min. Uniformity of dosage units is assessed according to Ph. Eur. 2.9.40 with an acceptance value ≤ 15. Magnesium stearate is limited to 0.25–0.5% w/w and is passed through a 500 µm sieve before final blending to prevent hydrophobic agglomeration on tablet surfaces. Compression is carried out on 6 mm round biconvex tooling with pre-compression force between 2 kN and 4 kN and main compression force between 8 kN and 15 kN; tablet hardness is maintained between 60 N and 90 N, and friability remains below 0.8% under Ph. Eur. 2.9.7. Disintegration testing per Ph. Eur. 2.9.1 completes within 15 min in 37°C water. Primary packaging in PVC/PVDC blisters with a desiccant pouch is used because lactose-based formulations gain hardness and slow disintegration at relative humidity above 60%. Batch records specify sieve analysis of the API lot before use; if D90 exceeds 20 µm, the lot is re-milled and re-tested before weighing. Loss-on-drying is checked before compression, with target below 2.0% w/w for the final blend.

Why Does Terminal Moist-Heat Sterilization Enlarge Benzoylurea Suspension Crystals?

Terminal moist-heat sterilization of flufenoxuron aqueous suspensions at 121°C for 15 min can increase mean crystal size through Ostwald ripening when the vehicle is not saturated with the active prior to sterilization. Aqueous solubility of the benzoylurea is below 0.1 mg/L at 25°C, so dissolution and recrystallization during the heat cycle are kinetically limited but remain measurable by laser diffraction after cooling. To minimize post-sterilization particle growth, the suspension is bead-milled with 0.3 mm yttria-stabilized zirconia media to a pre-sterilization particle size of D90 ≤ 10 µm and D50 ≤ 5 µm. The vehicle typically contains a non-ionic wetting agent at 0.1–0.2% w/v, a cellulosic suspending agent, and a tonicity-adjusting agent to 290–310 mOsm/kg. Syringeability is tested through a 21 G needle; the viscosity of the finished suspension is kept below 50 mPa·s at 25°C to avoid withdrawal force excursions. Sterility is verified by membrane filtration per Ph. Eur. 2.6.1 or direct inoculation per USP <71>, and bacterial endotoxin testing is conducted according to Ph. Eur. 2.6.14 or USP <85> with an endotoxin limit established in the registration file. Published data for terminal sterilization of flufenoxuron injectable suspensions at production scale is limited; therefore, process qualification runs must verify post-sterilization particle size rather than rely on laboratory-scale predictive models. If D90 after sterilization exceeds the acceptance criterion, the batch is rejected because syringe clogging risk increases disproportionately with crystal length above 10 µm. The suspension is filled into Type I glass vials with elastomeric closures coated with polytetrafluoroethylene to minimise sorption of the hydrophobic active onto closure surfaces.

Capsule Filling Electrostatics and Dose Uniformity in Low-Bulk-Density Blends

On intermittent dosator capsule fillers, flufenoxuron blends with spray-dried lactose and microcrystalline cellulose exhibit bulk density between 0.35 g/cm³ and 0.55 g/cm³, which complicates plug formation at fill weights below 200 mg. The API is pre-dispersed with colloidal silicon dioxide at 0.2–0.5% w/w before being combined with the filler; this step reduces electrostatic adhesion to stainless steel contact surfaces. Relative humidity in the encapsulation suite is maintained between 40% and 50% RH to prevent gelatin capsule shell softening at the higher end and static charge accumulation at the lower end. Lubrication is achieved with 0.25–0.5% w/w magnesium stearate; excessive lubricant is avoided because it coats the hydrophobic API and retards dissolution. Content uniformity is assessed according to USP <905> or Ph. Eur. 2.9.40, with an acceptance value ≤ 15 for low-dose capsules. Dissolution testing uses USP <711> Apparatus 2 at 50 rpm in 900 mL of pH 6.8 phosphate buffer containing 0.5% w/v sodium lauryl sulfate at 37°C; samples are withdrawn at 10, 20, 30, and 45 min with a common acceptance criterion of not less than 80% at 45 min for poorly soluble oral capsules. Capsule shells are stored at moisture content below 13% w/w before filling; brittle fracture occurs at low moisture and is monitored by shell hardness testing on a capsule tensile tester. Batch-to-batch variance in API particle size is a primary cause of dissolution failures, so incoming API lots are tested for particle size distribution by laser diffraction before use. Microbiological quality of the filled capsules is verified according to Ph. Eur. 5.1.4 or USP <61> and USP <62>.

Premix lines producing flufenoxuron medicated feed intermediates for production animal ectoparasite programmes operate with carrier selection based on bulk density and particle size matching. When the active is added at low mass fractions, a stepwise mixing protocol is used: the API is first combined with a carrier such as calcium carbonate or maize starch in a 50 L drum blender or high-shear mixer for 10–15 min, then transferred to a ribbon mixer or paddle mixer for dilution to final batch size. Homogeneity is checked by taking 10 spot samples according to ISO 6497:2002; the coefficient of variation of API content should not exceed 5%. Carryover prevention is governed by Regulation (EC) No 183/2005; the line is flushed with unmedicated carrier after every batch, and rinsate or first-flush material is collected for residue analysis. LC-MS/MS methods for benzoylureas in feed matrices routinely achieve limits of quantification between 0.01 mg/kg and 0.1 mg/kg, which supports verification of line clearance. Dust extraction is used at transfer points because the milled API is a low-dose dust hazard and because cross-contamination into subsequent non-target batches can occur through air handling systems. Batch records define maximum mixer fill volume, typically not exceeding 70% of mixer working capacity, to prevent dead zones in ribbon mixers. If the bulk density difference between carrier and API exceeds 0.3 g/cm³, segregation is controlled by reducing mixer discharge height and avoiding vibratory feeders.

When unit-dose powder sachets are filled with flufenoxuron for oral administration, the manufacturing suite is held at controlled relative humidity because the API is hydrophobic and the lactose-based diluent becomes cohesive above 55% RH. Each sachet fill weight is typically between 0.5 g and 5.0 g; the API is incorporated by geometric dilution in a low-shear mixer to avoid segregation. Uniformity of mass is verified according to Ph. Eur. 2.9.5 or USP <905>; for single-dose powders, the acceptable variation depends on fill weight and is defined in the pharmacopoeial general chapter. Sachet material is a heat-sealable aluminium foil laminate with a moisture vapour transmission rate below 0.1 g/m² per 24 h at 38°C and 90% RH; desiccant is not usually required unless the product is packed in a secondary carton for tropical climates. The powder is reconstituted with potable water at the point of administration, and the resulting suspension is used immediately because sedimentation of the active occurs within 10–15 min without a suspending agent. For this reason, label instructions specify vigorous shaking before dosing and rinsing of the dosing vessel with water to recover residual active. Loss on drying of the bulk powder is checked before filling, and the filling line is equipped with an in-line checkweigher to reject sachets outside the set fill weight range. Dust extraction and operator exposure monitoring follow local health and safety requirements for benzoylurea handling.

When Granule Drying Exceeds 60°C, Residual Moisture Drives Binder Migration

Wet granulation of flufenoxuron for oral granules uses a binder solution of povidone or pregelatinized starch in a high-shear mixer, with water addition controlled to produce a granule mass suitable for extrusion or wet screening. After granulation, the wet mass is dried in a fluid-bed dryer with inlet air temperature set between 45°C and 55°C; drying above 60°C causes binder migration to the granule surface, which can carry the hydrophobic API with it and produce non-uniform distribution. Dried granules are sized through a 1.0 mm screen and retained on a 250 µm screen; sieve analysis is conducted according to ISO 3310-1 or USP <786>, with at least 90% of the granule mass within the target fraction. Loss on drying is controlled to 1.0–2.5% w/w; lower moisture can increase granule friability and dust formation, while higher moisture can cause sticking during packaging. The granules are filled into HDPE bottles with induction-sealed caps and silica gel desiccant canisters. Content uniformity of the granulated material is assessed before filling by taking 10 random samples from the finished batch; acceptance value ≤ 15 is applied if the granule container is a single-dose unit, whereas bulk multi-dose granules are tested under blend uniformity protocols. Dissolution testing for granules is performed using the same medium as the capsule product; however, granule deaggregation may require a basket assembly at 100 rpm or a paddle apparatus at 75 rpm depending on the formulation. Published data on dissolution performance of flufenoxuron granules specifically is limited; product-specific validation is required.

Oral Solution Photodegradation Requires Amber Glass and pH Buffering Below 4.5

In oral solution formulations, flufenoxuron is co-solubilized in a vehicle comprising propylene glycol or glycerol formal with a small fraction of ethanol and an aqueous buffer. The benzoylurea chromophore is sensitive to ultraviolet light, so the finished solution is filled into amber Type III glass or opaque PET bottles; photostability is confirmed according to ICH Q1B at an illumination of not less than 1.2 million lux-hours and an ultraviolet energy of not less than 200 W·h/m². The buffer is maintained at pH 4.0–4.5 because alkaline hydrolysis of the benzoylurea bond accelerates above pH 6.0; citrate or acetate buffers at 10–50 mM are used. Antimicrobial preservative effectiveness is evaluated according to Ph. Eur. 5.1.3 or USP <51>, with challenge organisms including Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Candida albicans, and Aspergillus brasiliensis. Dosing accuracy for multi-dose oral solutions is verified by dropper or measuring syringe; deliverable volume tolerance is set according to the product monograph. Viscosity is adjusted with a hydrophilic polymer to extend contact time after oral administration, but the final dynamic viscosity remains below 100 mPa·s at 25°C to permit accurate withdrawal through a dosing pipette. Forced degradation studies under heat, acid, base, and peroxide are used to establish the analytical specificity of the HPLC method; base degradation samples are neutralized before injection to protect the column.